Loading
Ipsoprubart is an experimental antibody from Electra Therapeutics, in phase 1 trials for relapsed or refractory T-cell and NK-cell cancers.
Ipsoprubart (ELA026) is a monoclonal antibody from Electra Therapeutics. Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease. Its lead use is secondary haemophagocytic lymphohistiocytosis, an immune disorder that is not a cancer, in a phase 2/3 study. Its cancer use is a phase 1 study (NCT07465835) in relapsed or refractory T-cell and NK-cell malignancies. Whether it works in people has not been established.
Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease. Connects to SIRPA.
1.Ipsoprubart binds SIRPA.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ipsoprubart" OR ABSTRACT:"Ipsoprubart" OR TITLE:"ELA026" OR ABSTRACT:"ELA026") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ipsoprubart, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/